Skip to main content

Privacy Policy

At E-Pharma Times, accessible from this website, we are committed to protecting your privacy. This Privacy Policy explains what information we collect and how we use it.

Information We Collect

We may collect personal information such as your name or email ONLY when you voluntarily submit it through forms, comments, or subscriptions. We may also collect non-personal data such as IP address, browser type, device information, and pages visited for analytics and site improvement.

Cookies

We use cookies to enhance user experience and analyze website traffic. You may disable cookies through your browser settings.

Third-Party Services

We may display ads from Google AdSense or other third-party networks. These partners may use cookies to personalize ads based on your browsing behavior.

External Links

Our website may contain links to external websites. We are not responsible for their privacy practices.

Data Protection

We do not sell or share your personal information with anyone except trusted partners required for site operation.

Consent

By using our website, you consent to our Privacy Policy.

Updates

This Privacy Policy may be updated regularly. Last updated: 2025.

Comments

Post a Comment

Popular posts from this blog

Ozempic Litigation Update: Brazil Court Confirms 2026 Patent Expiry Litigation Update: Brazil Court Confirms 2026 Expiry for Ozempic Patents Posted on December 18, 2025 The global battle over GLP-1 receptor agonist patents has reached a critical milestone in South America. In a decisive move that will reshape the obesity and diabetes market, Brazilian courts have effectively confirmed that the patent exclusivity for semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) will end in March 2026 . For pharmaceutical investors, patients, and generic manufacturers, here is the breakdown of the recent litigation landscape in Brazil. The Core Decision: Extension Denied Novo Nordisk, the manufacturer of Ozempic, had sought to extend the validity of its Brazilian patents beyond the standard 20-year term. Their argument was...
Post a Comment
Read more

Transforming Healthcare: The Role of Artificial Intelligence in Pharmaceuticals and Medical Devices.

AI in Healthcare & Pharma: How Artificial Intelligence Is Transforming Drug Discovery and Medical Devices Artificial Intelligence (AI) is reshaping the global healthcare ecosystem. From drug discovery to diagnostics and patient care, AI has become the driving force behind the next wave of innovation in the pharmaceutical and medical device sectors. This article explores how AI technologies are transforming every stage of the healthcare value chain. AI in Pharmaceutical Development Accelerating Drug Discovery AI algorithms now analyze massive biological and chemical datasets to identify potential drug candidates in record time. Machine learning models predict molecular properties, toxicity levels, and drug–target interactions — drastically reducing preclinical failure rates. Major pharma companies are partnering with AI startups to shorten drug discovery timelines by up to 50%. Optimizing Clinical Trials AI supports patient selection, risk prediction, and real-time tr...
Post a Comment
Read more

Provention bio with Sanofi as its Marketing partner Grand long awaited FDA nod for "Teplizumab", a drug developed to combat juvenile diabetes

The immunotherapy, which delays the progression of type 1 diabetes, will be available to patients age 8 and older who are in stage 2 of the disorder. It becomes the first drug approved to delay progression of type 1 diabetes. https://www.fiercepharma.com/pharma/provention-bio-wins-long-awaited-fda-approval-type-1-diabetes-drug
Post a Comment
Read more